MedPath

Gonadorelin

Generic Name
Gonadorelin
Brand Names
Lutrepulse
Drug Type
Small Molecule
Chemical Formula
C55H75N17O13
CAS Number
33515-09-2
Unique Ingredient Identifier
9O7312W37G
Background

Gonadorelin is another name for gonadotropin-releasing hormone (GnRH). It is a synthetic decapeptide prepared using solid phase peptide synthesis. GnRH is responsible for the release of follicle stimulating hormone and leutinizing hormone from the anterior pituitary.

Indication

For evaluating the functional capacity and response of the gonadotropes of the anterior pituitary also for evaluating residual gonadotropic function of the pituitary following removal of a pituitary tumor by surgery and/or irradiation.

Associated Therapies
Ovulation induction therapy

Progesterone Primed Ovarian Stimulation Versus GnRH Antagonist Protocols in Women with Polycystic Ovarian Syndrome

Completed
Conditions
Controlled Ovarian Hyperstimulation
Polycystic Ovarian Syndrome
Interventions
First Posted Date
2025-02-06
Last Posted Date
2025-02-25
Lead Sponsor
El Shatby University Hospital for Obstetrics and Gynecology
Target Recruit Count
100
Registration Number
NCT06812559
Locations
🇪🇬

ELShatby University Hospital, Alexandria, Egypt

Comparison of Progestin Primed Ovarian Stimulation (PPOS) vs.GnRH Antagonist Methods on IVF Outcomes

Phase 4
Not yet recruiting
Conditions
IVF
Fertility Issues
Infertility
Interventions
First Posted Date
2024-05-02
Last Posted Date
2024-07-17
Lead Sponsor
Nesta Clinic
Target Recruit Count
152
Registration Number
NCT06396390
Locations
🇹🇷

Nesta Clinic, Istanbul, Sisli, Turkey

GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Atypical Hyperplasia Patients

Phase 2
Recruiting
Conditions
Obesity
Progesterone Resistance
Atypical Endometrial Hyperplasia
Interventions
First Posted Date
2024-04-30
Last Posted Date
2024-08-01
Lead Sponsor
Xiaojun Chen
Target Recruit Count
29
Registration Number
NCT06390904
Locations
🇨🇳

Obstetrics and Gynecology Hospital, Fudan University, Shanghai, China

🇨🇳

Tenth People's Hospital of Tongji University, Shanghai, Shanghai, China

NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

Phase 1
Recruiting
Conditions
Metastatic Neuroendocrine Prostate Cancer
Interventions
First Posted Date
2024-04-23
Last Posted Date
2025-04-04
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
36
Registration Number
NCT06379217
Locations
🇺🇸

Seattle Cancer Care Alliance, Seattle, Washington, United States

🇺🇸

Nebraska Cancer Specialists, Omaha, Nebraska, United States

🇺🇸

Memorial Sloan Kettering Cancer Ctr, New York, New York, United States

and more 1 locations

GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients

Phase 2
Recruiting
Conditions
Atypical Endometrial Hyperplasia
Progesterone Resistance
Obesity
Endometrial Neoplasms
Interventions
First Posted Date
2024-04-23
Last Posted Date
2024-08-01
Lead Sponsor
Xiaojun Chen
Target Recruit Count
29
Registration Number
NCT06379113
Locations
🇨🇳

Tenth People's Hospital of Tongji University, Shanghai, Shanghai, China

🇨🇳

Obstetrics and Gynecology Hospital, Fudan University, Shanghai, China

Dydrogesterone Versus GnRH Antagonist in Poor Responders Undergoing Double Ovarian Stimulation

Phase 2
Not yet recruiting
Conditions
Infertility
Interventions
Drug: Progestin primed ovarian stimulation
First Posted Date
2024-01-18
Last Posted Date
2024-01-23
Lead Sponsor
Bedaya Hospital
Target Recruit Count
120
Registration Number
NCT06212102
Locations
🇪🇬

Bedaya Hospital, Giza, Egypt

Recall by Genotype: Neuropeptide Stimulation

Phase 1
Terminated
Conditions
Reproductive Disorder
Interventions
First Posted Date
2023-06-13
Last Posted Date
2024-06-03
Lead Sponsor
Stephanie B. Seminara, MD
Target Recruit Count
16
Registration Number
NCT05901467
Locations
🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

Two Different Types of Luteal Phase Support in Natural Cycle Frozen Embryo Transfer and Its Effect on Pregnancy Rates

Not Applicable
Recruiting
Conditions
Luteal Phase Support
Interventions
First Posted Date
2023-05-01
Last Posted Date
2023-05-01
Lead Sponsor
Shaare Zedek Medical Center
Target Recruit Count
144
Registration Number
NCT05838105
Locations
🇮🇱

Shaare Zedek medical center, Jerusalem, Israel

Exploring the Relationship Between Androgen Metabolism, Metabolic Disease and Skeletal Muscle Energy Balance in Men

Not yet recruiting
Conditions
Testosterone Deficiency
Metabolic Disturbance
Cardiovascular Diseases
Diabetes
Hypogonadism, Male
Androgen Deficiency
Metabolic Disease
Obesity
NAFLD
Prostate Cancer
Interventions
First Posted Date
2023-03-17
Last Posted Date
2023-03-17
Lead Sponsor
Royal College of Surgeons, Ireland
Target Recruit Count
60
Registration Number
NCT05773183
Locations
🇮🇪

Beaumont Hospital, Dublin 9, Ireland

Effect of GH Supplementation on the Blastocyst Euploid Rate in AMA Patients--A Retrospective Cohort Study

Phase 3
Completed
Conditions
Advanced Maternal Age
PGT-A
Growth Hormone
Interventions
First Posted Date
2022-10-12
Last Posted Date
2023-02-21
Lead Sponsor
ShangHai Ji Ai Genetics & IVF Institute
Target Recruit Count
692
Registration Number
NCT05574894
Locations
🇨🇳

Shanghai JIAI Genetics and IVF Institute, Shanghai, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath